Two Sigma Investments
MNPR icon

Two Sigma Investments’s Monopar Therapeutics MNPR Stock Holding History

Two Sigma Investments’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$535K Buy
9,765
+4,776
+96% +$288K ﹤0.01% 3696
2025
Q4 		$326K Buy
+4,989
New +$408K ﹤0.01% 3541
2024
Q1 		– Sell
-2,860
Closed -$4.87K – 3244
2023
Q4 		$4.87K Buy
+2,860
New +$5.79K ﹤0.01% 3103

Other funds holding MNPR

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments's MNPR Position: Q1 2026 in Review

Two Sigma Investments increased its Monopar Therapeutics (MNPR) stake by 96% in Q1 2026, buying an estimated $288K and bringing the position to 9,765 shares worth $535K. The position accounts for ﹤0.01% of the portfolio, ranked #3696.

Two Sigma Investments first reported a position in MNPR in Q4 2023 and has held it in 3 quarters since. 82 funds tracked by Wall St. Rank hold MNPR as of Q1 2026.

  • Two Sigma Investments held 9,765 shares of Monopar Therapeutics worth $535K as of Q1 2026.
  • Two Sigma Investments bought 4,776 Monopar Therapeutics shares in Q1 2026, an estimated $288K.
  • Monopar Therapeutics made up ﹤0.01% of Two Sigma Investments's portfolio in Q1 2026, its #3696 holding.
  • Two Sigma Investments first reported a position in Monopar Therapeutics in Q4 2023 and has held it in 3 quarters since.
  • 82 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q1 2026.

Based on Two Sigma Investments's 13F filing for Q1 2026, filed 15 May 2026.